Ticker Details
Protagonist Therapeutics, Inc. Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company with a proprietary peptide-based technology platform focused on discovering and developing new chemical entities to address significant unmet medical needs.
IPO Date:	August 11, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$8.85B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.74 | 3.07%
Avg Daily Range (30 D):	$2.64 | 2.41%
Avg Daily Range (90 D):	$2.51 | 2.44%

Institutional Daily Volume
Avg Daily Volume:	.5M
Avg Daily Volume (30 D):	.54M
Avg Daily Volume (90 D):	.53M

Trade Size
Avg Trade Size (Sh.):	70
Avg Trade Size (Sh.) (30 D):	45
Avg Trade Size (Sh.) (90 D):	44

Institutional Trades
Total Institutional Trades:	3,421
Avg Institutional Trade:	$3.66M
Avg Institutional Trade (30 D):	$10.93M
Avg Institutional Trade (90 D):	$10.39M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.62M
Avg Closing Trade (30 D):	$23.05M
Avg Closing Trade (90 D):	$19.22M
Avg Closing Volume:	150.26K

News

Apr 22, 2026 @ 5:00 PM Polycythemia Vera Market Set for Transformation: K... Source: Delveinsight

Apr 2, 2026 @ 10:14 AM This Healthcare Stock Barely Flinches During Marke... Source: James Halley

Mar 19, 2026 @ 12:25 PM Johnson & Johnson-Protagonist Therapeutics Partner... Source: Vandana Singh

Feb 25, 2026 @ 8:28 PM Protagonist Stock Up 120%, but One Fund Just Revea... Source: Jonathan Ponciano

Oct 23, 2025 @ 6:25 PM Moody Aldrich Dumps Entire Stake in Chart Industri... Source: Adam Palasciano

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-1.81	$.06	$-.7
Diluted EPS	$-1.82	$.05	$-.7
Revenue	$74.06M	$56.37M	$7.44M
Gross Profit
Net Income / Loss	$-114.71M	$3.78M	$-44.38M
Operating Income / Loss	$-142.47M	$-3.65M	$-50.36M
Cost of Revenue
Net Cash Flow	$54.12M	$65.32M	$14.68M
PE Ratio